Prime Medicine, Inc.
PRME
$3.09
-$0.08-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 34.81% | 2.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.81% | 2.15% | |||
| Cost of Revenue | -2.08% | -1.74% | |||
| Gross Profit | 3.03% | 1.84% | |||
| SG&A Expenses | -36.56% | 18.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.73% | 4.17% | |||
| Operating Income | 14.55% | -4.21% | |||
| Income Before Tax | 14.28% | -6.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.28% | -6.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.28% | -6.60% | |||
| EBIT | 14.55% | -4.21% | |||
| EBITDA | 14.96% | -4.42% | |||
| EPS Basic | 14.35% | -6.73% | |||
| Normalized Basic EPS | 14.46% | -4.54% | |||
| EPS Diluted | 14.35% | -6.73% | |||
| Normalized Diluted EPS | 14.46% | -4.54% | |||
| Average Basic Shares Outstanding | 0.07% | -0.11% | |||
| Average Diluted Shares Outstanding | 0.07% | -0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||